Birkenstock Holding plc (NYSE:BIRK – Free Report) – Equities researchers at William Blair cut their Q4 2024 earnings estimates for shares of Birkenstock in a research note issued to investors on Tuesday, December 10th. William Blair analyst S. Zackfia now anticipates that the company will post earnings of $0.24 per share for the quarter, down from their previous estimate of $0.25. The consensus estimate for Birkenstock’s current full-year earnings is $1.36 per share. William Blair also issued estimates for Birkenstock’s Q2 2025 earnings at $0.60 EPS, Q3 2025 earnings at $0.69 EPS, Q4 2025 earnings at $0.37 EPS, FY2025 earnings at $1.83 EPS and Q1 2026 earnings at $2.41 EPS.
Several other brokerages also recently issued reports on BIRK. Hsbc Global Res raised shares of Birkenstock to a “strong-buy” rating in a report on Tuesday, December 3rd. UBS Group lowered their price target on Birkenstock from $85.00 to $83.00 and set a “buy” rating for the company in a report on Tuesday, December 10th. HSBC raised Birkenstock from a “hold” rating to a “buy” rating and increased their target price for the stock from $58.00 to $60.00 in a research report on Tuesday, December 3rd. BMO Capital Markets reaffirmed an “outperform” rating and set a $60.00 price target on shares of Birkenstock in a research report on Friday, August 30th. Finally, Evercore ISI restated an “outperform” rating and set a $77.00 price objective (up previously from $63.00) on shares of Birkenstock in a research note on Monday, August 26th. Two analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $66.13.
Birkenstock Trading Up 2.7 %
Shares of Birkenstock stock opened at $55.06 on Friday. Birkenstock has a 12-month low of $41.00 and a 12-month high of $64.78. The stock has a market cap of $10.34 billion, a PE ratio of 90.26, a price-to-earnings-growth ratio of 1.19 and a beta of 2.22. The company has a 50-day moving average of $49.31 and a two-hundred day moving average of $53.01. The company has a current ratio of 2.91, a quick ratio of 1.49 and a debt-to-equity ratio of 0.55.
Institutional Trading of Birkenstock
A number of institutional investors have recently added to or reduced their stakes in BIRK. Bank of New York Mellon Corp boosted its position in Birkenstock by 19.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 62,776 shares of the company’s stock valued at $3,416,000 after buying an additional 10,157 shares during the period. Principal Financial Group Inc. bought a new position in shares of Birkenstock in the 2nd quarter valued at about $4,323,000. TD Asset Management Inc lifted its holdings in shares of Birkenstock by 22.6% in the 2nd quarter. TD Asset Management Inc now owns 244,372 shares of the company’s stock worth $13,296,000 after acquiring an additional 45,000 shares during the last quarter. Victory Capital Management Inc. purchased a new stake in shares of Birkenstock in the second quarter worth approximately $18,755,000. Finally, Acadian Asset Management LLC purchased a new stake in Birkenstock in the second quarter worth $136,000. Hedge funds and other institutional investors own 19.93% of the company’s stock.
Birkenstock Company Profile
Birkenstock Holding plc manufactures and sells footwear products. It also offers sandals, shoes, closed-toe silhouettes, skincare products, and accessories. The company sells its products through e-commerce sites and a network of owned retail stores, as well as business-to-business channels. It operates in the United States, Brazil, Canada, Mexico, Europe, APMA, and internationally.
Recommended Stories
- Five stocks we like better than Birkenstock
- What Does Downgrade Mean in Investing?
- Why Hershey Stock Has More Room to Run Despite Takeover Rejection
- What is the Euro STOXX 50 Index?
- Texas Instruments: The Old-School Tech Titan Still Delivering
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- GRAIL: Biotech Stock Targeting $100B Cancer Market
Receive News & Ratings for Birkenstock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Birkenstock and related companies with MarketBeat.com's FREE daily email newsletter.